AEYE Health receives clearance for the first artificial intelligence solution to allow fully autonomous screening for diabetic retinopathy using a portable device.
An analysis presented at ADA 2023 suggests autonomous artificial intelligence testing for diabetic eye diseases promoted health equity across various patient subgroups.